Imfinzi, Imjudo approved in Japan for 3 cancers
28 December 2022 07:00 GMT Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers Approvals based on significant survival benefits inHIMALAYA, POSEIDON and TOPAZ-1 Phase III trials AstraZeneca's immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung. The approvals authorise Imfinzi in combination with Imjudo for the treatment of adult patients with